MedTrace Logo

Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies

NCT05598788 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2023-05-03

No results posted yet for this study

Summary

The MISTIK project aims at clinically validating the technique of oral anticancer drugs determination by volumetric absorptive micro-sampling and at comparing the results to measurements performed on venous samples.

Conditions

  • Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

Interventions

OTHER

Measurement of drug concentrations

Measurement of anti-cancer drug concentrations using volumetric absorptive micro-sampling (VAMS) and venous blood sample

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • VERDIER Marie-Clemence · Rennes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-03
Primary Completion
2023-12-01
Completion
2023-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05598788 on ClinicalTrials.gov